Answers are grounded in this paper and cite their sources.
Diquat (DQ) poisoning can cause severe multi-organ injury, and no specific antidote is currently available. Medicinal charcoal (MC) is used for gastrointestinal decontamination, but evidence regarding the effects of different administration times and doses remains limited. Methods: Sixty male Sprague-Dawley rats were allocated to six groups: control, DQ exposure (115.5 mg/kg), gastric lavage (GL), low-dose MC (94.5 mg/kg) administered 1 h (ML1) or 2 h (ML2) after exposure, and high-dose MC (315 mg/kg) administered 1 h after exposure (MH1). At 12 h after DQ exposure, circulating DQ concentrations, hepatic and renal biochemical markers, histopathological changes, intestinal tight-junction proteins, inflammatory gene expression, gut microbiota composition, and intestinal and blood transcriptomic and metabolomic profiles were evaluated. Results: DQ exposure was associated with hepatic, renal, and intestinal injury, alterations in intestinal tight-junction protein expression, inflammatory responses, and changes in gut microbial composition and molecular profiles. Among the intervention regimens evaluated, the ML1 group showed the lowest mean circulating DQ concentration at 12 h and relatively favorable changes in several injury-related outcomes. However, the treatment-associated effects were not consistent across all measured parameters, and MC administration did not uniformly restore gut microbial diversity. Integrated transcriptomic and metabolomic analyses identified associations involving inflammatory responses, mitochondrial function-related genes, and lipid metabolic pathways. Conclusions: Early low-dose MC administration was associated with relatively favorable outcomes among the treatment conditions examined in this acute rat model of DQ poisoning. The findings provide exploratory evidence regarding the effects of MC on early DQ-associated injury and identify candidate molecular processes for future investigation. Larger studies incorporating longitudinal assessments, more comprehensive dose–time designs, and direct mechanistic validation are needed before definitive treatment or clinical recommendations can be established.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: